Join
Live feed
·
PRReleasevia Quantisnow
Ocular Therapeutix Inc. logo

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
OCUL· Ocular Therapeutix Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCUL (Ocular Therapeutix Inc.) and more on Quantisnow.